{"nctId":"NCT01500083","briefTitle":"Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia","startDateStruct":{"date":"2012-03"},"conditions":["Indolent Non-Hodgkin's Lymphoma","Chronic Lymphocytic Leukemia"],"count":90,"armGroups":[{"label":"Patients with Chronic Lymphocytic Leukemia (CLL)","type":"EXPERIMENTAL","interventionNames":["Drug: Bendamustine at a dose of 100 mg/m2"]},{"label":"Patients with Indolent Non-Hodgkin's Lymphoma (iNHL)","type":"EXPERIMENTAL","interventionNames":["Drug: Bendamustine at a dose of 120 mg/m2"]}],"interventions":[{"name":"Bendamustine at a dose of 100 mg/m2","otherNames":["Treanda®"]},{"name":"Bendamustine at a dose of 120 mg/m2","otherNames":["Treanda®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria for iNHL:\n\n* The patient has biopsy-confirmed diagnosis of indolent B-cell NHL documented as relapsed or refractory iNHL (following rituximab-based therapy).\n* The patient has one of the following types of indolent B-cell lymphoma:\n\n  * follicular lymphoma grade 1, 2, or 3A\n  * marginal zone lymphoma\n  * lymphoplasmacytic lymphoma\n  * small lymphocytic lymphoma\n* The patient has adequate haematologic function (unless abnormalities are related to lymphoma involvement of the bone marrow or hypersplenism caused by lymphoma).\n\nInclusion Criteria for CLL:\n\n* The patient has previously confirmed (according to WHO criteria) untreated symptomatic chronic B-cell lymphocytic leukemia Binet Stage B or Binet Stage C or Rai stage II to IV in need of medical treatment.\n* The patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n\nExclusion Criteria:\n\n* The patient has participated in a clinical study \\<30 days prior to the Screening Visit.\n* The patient has one or more of the following conditions:\n\n  * active transformed lymphoma\n  * any history of central nervous system or leptomeningeal lymphoma\n  * an active malignancy other than the target cancer within the past 5 years\n  * human immunodeficiency virus\n* The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.\n\nOther inclusion and exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"298","spread":null},{"groupId":"OG001","value":"302","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":16},"commonTop":["Nausea","Fatigue","Vomiting","Diarrhoea","Neutropenia"]}}}